Overview
Neuronal survival depends on precise metabolic control. The brain, despite comprising only about 2% of body weight, consumes approximately 20% of the body's resting metabolic energy, reflecting the extraordinary energy demands of neural signaling, maintenance, and homeostasis[@attwell2001]. Dysregulation of glucose metabolism, mitochondrial function, and nutrient sensing contributes significantly to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders[@cunnane2020]. This page explores the metabolic pathways central to neuronal health and how their dysfunction drives neurodegeneration.
The concept of metabolic dysfunction in neurodegeneration has evolved from early observations of reduced cerebral glucose uptake to a sophisticated understanding of how impaired energy metabolism intersects with protein aggregation, neuroinflammation, and synaptic failure[@sweeney2018]. This intersection represents a fundamental nexus where multiple disease mechanisms converge, making metabolic pathways attractive therapeutic targets.
Overview of Cerebral Energy Consumption
The brain's energy demands are remarkably high and precisely regulated. Neurons, the primary computational units of the brain, maintain steep ionic gradients across their membranes through the action of Na+/K+ ATPases, consuming approximately 60-80% of cortical energy for this purpose alone[@ames2000]. Action potentials and synaptic transmission account for additional substantial energy expenditure, while baseline cellular maintenance functions consume the remainder.
This high metabolic demand requires continuous and reliable energy supply, primarily in the form of adenosine triphosphate (ATP) generated through oxidative phosphorylation in mitochondria. However, neurons cannot store significant energy reserves, making them dependent on continuous blood-borne glucose delivery[@van2016]. This metabolic vulnerability underlies the brain's sensitivity to hypoxia, hypoglycemia, and mitochondrial dysfunction.
Glycolysis
Glycolysis converts glucose to pyruvate through a series of ten enzymatic reactions, generating a net of 2 ATP molecules per glucose molecule[@mergenthaler2013]. While inefficient compared to oxidative phosphorylation, glycolysis serves critical functions:
- Rapid ATP generation: Glycolysis can produce ATP quickly when needed
- Biosynthetic precursors: Metabolic intermediates feed into biosynthetic pathways
- Oxygen-independent operation: Can function under hypoxic conditions
- Pentose phosphate pathway branch: Provides NADPH and ribose for biosynthesis
In neurons, glycolysis is particularly important because mitochondria in neurons are more prone to releasing cytochrome c and triggering apoptosis compared to other cell types[@nicholls2009]. This makes neurons partially dependent on glycolytic ATP for survival.
Tricarboxylic Acid Cycle
The tricarboxylic acid (TCA) cycle, also known as the Krebs cycle or citric acid cycle, completes the oxidation of glucose-derived pyruvate, generating:
- 2 ATP equivalents (GTP) per glucose
- 6 NADH and 2 FADH2 for oxidative phosphorylation
- Metabolic intermediates for biosynthesis
The TCA cycle operates in the mitochondrial matrix and requires continuous supply of acetyl-CoA from pyruvate, fatty acids, or amino acids[@shulman2020]. Key regulatory points include:
- Citrate synthase: Primary regulatory enzyme
- Isocitrate dehydrogenase: NAD+-dependent, sensitive to ATP/ADP ratio
- α-ketoglutarate dehydrogenase: Rate-limiting, sensitive to NADH
Oxidative Phosphorylation
Oxidative phosphorylation couples the oxidation of NADH and FADH2 to ATP synthesis through the electron transport chain (ETC)[@saraste1999]. The ETC comprises four complexes (I-IV) that sequentially transfer electrons from donors to oxygen, creating a proton gradient across the inner mitochondrial membrane. Complex V (ATP synthase) uses this gradient to synthesize ATP.
In neurons, oxidative phosphorylation primarily occurs in dendrites and near synapses, where energy demands are highest[@kann2006]. Mitochondrial distribution and dynamics (fusion/fission) are carefully regulated to meet these spatially heterogeneous demands.
The traditional view of brain energy metabolism as neuron-centric has evolved to recognize the critical role of astrocytes, a major class of glial cells[@pellerin1994]. This metabolic partnership involves several key processes:
Astrocytes, but not neurons, store glycogen—the largest energy reserve in the brain[@brown2004]. Glycogenolysis can provide rapid energy during:
- Sustained neuronal activity
- Hypoglycemia
- Ischemia
Astrocyte glycogen is metabolized to lactate, which is then shuttled to neurons as an alternative fuel.
Lactate Shuttle Hypothesis
The lactate shuttle hypothesis proposes that astrocyte-derived lactate serves as a primary energy substrate for active neurons[@van2015]. According to this model:
Neuronal activity increases glutamate release
Glutamate uptake by astrocytes stimulates glycolysis
Lactate is released by astrocytes and taken up by neurons
Neurons oxidize lactate to meet increased energy demandsThis coupling ensures that energy supply matches demand across the neurovascular unit.
Glutamate-Glutamine Cycle
Glutamate, the primary excitatory neurotransmitter, is recycled through the glutamate-glutamine cycle[@hertz2009]. This process:
- Removes extracellular glutamate (preventing excitotoxicity)
- Provides metabolic energy for astrocytes
- Couples neurotransmitter recycling to cellular metabolism
For each glutamate molecule recycled, astrocytes expend approximately 1 ATP, linking neurotransmitter cycling directly to cellular energetics.
Evidence from Neuroimaging
FDG-PET Studies
Fluorodeoxyglucose positron emission tomography (FDG-PET) has established cerebral glucose hypometabolism as a hallmark of Alzheimer's disease[@mosconi2005]. Characteristic patterns include:
Early/Prodromal AD:
- Posterior cingulate cortex hypometabolism (earliest consistent finding)
- Hippocampal and entorhinal cortex hypometabolism
- Precuneus involvement
Established AD:
- Progressive hypometabolism extending to lateral parietal cortex
- Temporal lobe involvement
- Relative preservation of primary sensory and motor cortices
- Later involvement of frontal regions
These hypometabolic patterns correlate with clinical severity and precede clinical symptoms in at-risk individuals by years to decades[@jack2010].
Longitudinal Studies
Longitudinal FDG-PET studies reveal:
- Hypometabolism progresses in a characteristic pattern matching neurofibrillary tangle distribution
- Rate of hypometabolism predicts clinical progression
- Metabolic decline precedes structural atrophy in many cases
Insulin Resistance
Brain insulin resistance has emerged as a central mechanism in AD pathophysiology[@arnold2018]. The brain is an insulin-sensitive organ with widespread insulin receptor expression, particularly in the hippocampus, cerebral cortex, and cerebellum. Insulin signaling in the brain regulates:
- Synaptic plasticity and memory formation
- Glucose uptake and metabolism
- Neuronal survival
- Amyloid and tau metabolism
In AD brain, evidence of insulin resistance includes:
- Reduced IRS-1 (insulin receptor substrate 1) tyrosine phosphorylation
- Increased serine phosphorylation of IRS-1 (inhibitory)
- Decreased downstream PI3K/Akt signaling
- Altered expression of glucose transporters
This "type 3 diabetes" hypothesis proposes that brain insulin resistance contributes to AD pathogenesis through multiple pathways[@de2008].
Mitochondrial Dysfunction
Mitochondrial abnormalities are prominent in AD[@swerdlow2002]:
- Reduced Complex IV activity
- Increased mitochondrial DNA mutations
- Impaired calcium handling
- Reduced ATP production
- Enhanced reactive oxygen species (ROS) generation
Amyloid-beta (Aβ) directly interacts with mitochondria, impairing function, while tau pathology disrupts mitochondrial transport and distribution within neurons[@manczak2006].
Aβ oligomers and aggregates interfere with multiple aspects of glucose metabolism[@sheng2012]:
- GLUT trafficking: Aβ reduces GLUT3 and GLUT4 translocation
- Glycolytic enzymes: Aβ inhibits key glycolytic steps
- Mitochondrial function: Direct binding and functional impairment
- Insulin signaling: Aβ disrupts insulin receptor function
Glutamate Toxicity
Excessive glutamate stimulation consumes ATP through:
- Na+/K+ ATPase activation to restore ion gradients
- Increased metabolic demand for restored homeostasis
- Possible uncpling of mitochondrial function
This creates a vicious cycle where excitotoxicity impairs metabolism, and impaired metabolism reduces the brain's capacity to handle glutamate[@alano2010].
Therapeutic Implications
Understanding glucose hypometabolism has led to therapeutic strategies:
Intranasal Insulin:
- Delivers insulin directly to the brain
- Improves memory in AD and MCI patients
- Phase II trials showing promise[@craft2012]
Insulin Sensitizers:
- Metformin: Mixed results in clinical trials
- Thiazolidinediones: PPARγ agonists under investigation
Glucose Transport Enhancement:
- Targeting GLUT1/GLUT3 expression
- Small molecule GLUT activators in development
Early studies using FDG-PET revealed characteristic hypometabolism in the basal ganglia of PD patients[@eidelberg1995]:
- Posterior putamen (contralateral to most affected side)
- Caudate nucleus
- Midbrain (including substantia nigra)
This hypometabolism reflects:
- Dopaminergic neuron loss
- Reduced metabolic demand of denervated striatum
- Secondary effects on basal ganglia circuitry
As PD progresses, cortical hypometabolism develops:
- Premotor cortex
- Posterior parietal cortex
- Occipital cortex (especially visual cortex)
This pattern correlates with:
- Disease duration
- Cognitive impairment
- Development of Parkinson's disease dementia
Mitochondrial Complex I Deficiency
The most consistent biochemical abnormality in PD is reduced activity of mitochondrial Complex I[@schapira2007]. Evidence includes:
- Reduced Complex I activity in substantia nigra
- Decreased Complex I subunit expression
- Impaired Complex I assembly
This deficiency:
- Reduces ATP production
- Increases ROS generation
- Promotes neuronal death
- May relate to environmental toxin sensitivity
Type 2 Diabetes and PD Risk
Epidemiological studies consistently show that type 2 diabetes increases PD risk by 20-40%[@hu2007]. Shared features include:
- Insulin resistance
- Mitochondrial dysfunction
- Chronic inflammation
This association suggests common metabolic pathways may underlie both conditions.
Other Systemic Markers
PD patients often show:
- Altered fasting glucose levels
- Dyslipidemia
- Altered adipokine levels
- Changed gut microbiome (affecting metabolism)
These systemic changes may reflect:
- Subclinical metabolic dysfunction
- Effects of chronic dopaminergic therapy
- Disease-related autonomic changes
Therapeutic Implications
Metabolic approaches to PD include:
Mitochondrial Protectants:
- Coenzyme Q10: Mixed trial results
- Creatine: Under investigation
- Mitochondrial-targeted antioxidants
Metformin:
- May reduce PD risk in diabetics
- Potential neuroprotective effects
- Clinical trials ongoing
Ketogenic Approaches:
- May support neuronal metabolism
- May reduce motor symptoms
- Limited but promising data
Ketone Bodies as Alternative Fuel
When glucose availability is limited (fasting, ketogenic diet), the liver produces ketone bodies—beta-hydroxybutyrate and acetoacetate—which can serve as alternative fuel for the brain[@veech2004]. Ketone metabolism offers several advantages:
- Reduced ROS generation: Ketone oxidation produces fewer reactive oxygen species than glucose
- Improved mitochondrial efficiency: Ketone oxidation may be more efficient
- Alternative energy substrate: Bypasses impaired glucose metabolism
- Signaling functions: Ketone bodies have signaling properties beyond metabolism
Brain Ketone Uptake
Ketone bodies enter the brain via monocarboxylate transporters (MCTs)[@pierre2005]:
- MCT1: Endothelial cells of blood-brain barrier
- MCT2: Neuronal expression
- MCT4: Astrocyte expression
Expression and activity of these transporters can limit brain ketone uptake, particularly in aging.
Ketogenic Diet in Neurodegeneration
The ketogenic diet, high in fat and low in carbohydrates, induces ketogenesis and has been studied in neurodegenerative diseases[@broom2019].
Mechanisms of Benefit
Direct metabolic effects:
- Improved mitochondrial function
- Reduced oxidative stress
- Enhanced energy efficiency
Signaling effects:
- Increased GABA (reducing excitotoxicity)
- Enhanced BDNF expression
- Activated anti-inflammatory pathways
Protein homeostasis:
- Enhanced autophagy
- Improved proteostasis
Clinical Evidence
Alzheimer's Disease:
- Ketogenic diet improves cognition in mild cognitive impairment[@krikorian2012]
- Ketone supplementation (MCT) shows cognitive benefits
- Larger trials ongoing
Parkinson's Disease:
- Ketogenic diet may improve motor symptoms[@phillips2018]
- Limited but encouraging data
Ketone Supplements
Exogenous ketone supplements offer a less restrictive approach[@newport2015]:
- Beta-hydroxybutyrate salts
- Ketone esters
- Medium-chain triglyceride (MCT) oil
These can elevate circulating ketone levels without requiring strict dietary adherence.
Lipid Dysregulation in AD
The brain is rich in lipids, which are essential for:
- Membrane structure
- Myelin formation
- Synaptic function
- Signaling molecules
AD is associated with widespread lipid dysregulation[@chang2017]:
Cholesterol
Brain cholesterol metabolism is altered in AD:
- Reduced cholesterol synthesis
- Altered ApoE-mediated transport
- Relationship between cholesterol and amyloid processing
Sphingolipids
Ceramide accumulation is a consistent finding in AD[@cutler2004]:
- Promotes neuronal apoptosis
- Enhances amyloid toxicity
- Activates inflammatory pathways
Phospholipids
Membrane phospholipid alterations include:
- Reduced phosphatidylcholine
- Altered phosphatidylserine
- Changed polyunsaturated fatty acid levels
ApoE and Lipid Transport
Apolipoprotein E (ApoE) plays critical roles in brain lipid transport[@huang2012]:
ApoE isoforms:
- ApoE3: Most common, neutral risk
- ApoE4: Major genetic risk factor for AD
- ApoE2: May be protective
Functions:
- Cholesterol and phospholipid transport
- Amyloid clearance
- Synaptic repair and plasticity
- Neuroinflammation modulation
ApoE4 effects:
- Impaired lipid transport
- Reduced amyloid clearance
- Enhanced neuroinflammation
- Synaptic dysfunction
Glutamate/GABA Balance
The balance between excitatory (glutamate) and inhibitory (GABA) neurotransmission is fundamental to brain function and highly metabolically demanding[@schousboe2005].
Excitotoxicity
Excessive glutamate leads to:
- Calcium influx through NMDA receptors
- Mitochondrial overload
- ROS generation
- Activation of apoptotic pathways
Neuronal energy failure impairs the ability to maintain glutamate homeostasis, creating a vicious cycle[@choi2003].
Energy Failure Compensation
When energy is limited, neurons cannot maintain ion gradients, leading to:
- Depolarization (reducing the gradient for glutamate uptake)
- Release of glutamate
- Further activation of excitotoxic pathways
Tryptophan metabolism through the kynurenine pathway produces neuroactive metabolites[@schwarcz2012]:
- Quinolinic acid: NMDA agonist, neurotoxic
- Kynurenic acid: NMDA antagonist, neuroprotective
In neurodegenerative diseases:
- Increased quinolinic acid
- Elevated quinolinic/kynurenic acid ratio
- Potential for neurotoxicity
Therapeutic Approaches
Exercise
Exercise enhances brain metabolism through[@cotman2007]:
- Increased cerebral blood flow
- Elevated growth factor expression (BDNF, IGF-1)
- Enhanced mitochondrial biogenesis
- Improved insulin sensitivity
Regular exercise is associated with reduced AD risk and may slow progression.
Caloric Restriction
Caloric restriction extends lifespan and may improve brain health[@mattson2005]:
- Enhanced autophagy
- Reduced oxidative stress
- Improved metabolic health
- Increased neurotrophic factor expression
Dietary Interventions
- Mediterranean diet: Associated with reduced AD risk
- MIND diet: Specifically designed for brain health
- Time-restricted eating: Metabolic benefits
Pharmacological Approaches
Metformin:
- Improves insulin sensitivity
- May reduce dementia risk in diabetics
- Clinical trial results mixed
Targeted Antioxidants:
- Coenzyme Q10
- Alpha-lipoic acid
- Vitamin E
Mitochondrial Modulators:
- Pioglitazone (PPARγ agonist)
- Mitochondrial-targeted peptides
Future Directions
Metabolic therapies for neurodegeneration are evolving toward:
Personalized approaches: Based on metabolic phenotype
Combination therapies: Targeting multiple metabolic pathways
Biomarker development: Identifying patients most likely to benefit
Early intervention: Treating before irreversible damageCross-Disease Comparison Matrix
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|---------------------|
| Primary Metabolic Alteration | Glucose hypometabolism, insulin resistance | Glucose hypometabolism, mitochondrial dysfunction | Metabolic inflexibility, glycolytic shift | Glucose dysregulation, altered energy expenditure | Metabolic hyperactivity, increased energy expenditure |
| Key Enzymes Affected | IDHK, PDH, complex IV | Complex I, IDH, α-KGDH | Glycolytic enzymes, IDH | Various metabolic enzymes | IDH, metabolic enzymes |
| Brain Region Affected | Hippocampus, entorhinal cortex | Substantia nigra, striatum | Motor cortex, spinal cord | Frontal, temporal lobes | Striatum, cortex |
| Energy Crisis | Severe in early disease | Moderate, progressive | Severe in later stages | Variable | Progressive |
| Therapeutic Target | Ketogenic diet, metabolic modulators | Metabolic enhancers, CoQ10 | Metabolic support | Metabolic modulators | Metabolic inhibitors |
Amyotrophic Lateral Sclerosis
ALS exhibits metabolic inflexibility with a shift toward glycolytic metabolism. Patients often show hypermetabolism despite weight loss, indicating increased energy expenditure. Motor neurons are particularly vulnerable due to their large size and high metabolic demands.
Hypermetabolism in ALS: ALS patients exhibit resting energy expenditure approximately 15-25% higher than predicted based on body composition. This hypermetabolic state persists throughout disease progression and is independent of disease stage, respiratory function, or inflammatory markers. The hypermetabolic state creates a catabolic environment where patients lose weight despite adequate caloric intake. Weight loss, particularly loss of lean body mass, correlates with reduced survival and faster disease progression.
Motor Neuron Energy Demands: Motor neurons represent the largest cells in the central nervous system, with some extending axons over one meter in length. This extreme morphology creates unique metabolic challenges including continuous Na+/K+ ATPase activity and enormous energetic cost of action potential propagation.
Glycolytic Shift and Lactate Dynamics: ALS motor neurons exhibit a metabolic shift toward glycolysis, reflected by elevated lactate levels in the cerebrospinal fluid. This shift may represent an attempt to maintain ATP production despite impaired oxidative phosphorylation. However, glycolysis generates only 2 ATP per glucose molecule compared to 36 from complete oxidation.
Frontotemporal Dementia
FTD shows variable metabolic patterns depending on the subtype. Both hypometabolism and regional-specific metabolic changes have been documented.
Subtype-Specific Patterns: The three major FTD subtypes — behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and logopenic variant primary progressive aphasia (lvPPA) — exhibit distinct metabolic patterns on FDG-PET. bvFTD shows predominant frontal and anterior cingulate hypometabolism; svPPA demonstrates focal anterior temporal lobe hypometabolism; lvPPA shows left temporoparietal hypometabolism similar to typical AD.
Glucose Transporter Dysfunction: GLUT1 and GLUT3 dysfunction can impair glucose uptake and contribute to hypometabolism in FTD.
Relationship to Mitochondrial Dysfunction: Mitochondrial dysfunction is prominent in FTD, particularly in cases with tau pathology. The 4-repeat tau isoforms characteristic of CBD and PSP are associated with mitochondrial deficits. Tau directly interacts with mitochondria, impairing complex V activity and reducing ATP production.
Huntington's Disease
HD shows a paradoxical pattern of hypermetabolism despite progressive neurodegeneration. Patients exhibit increased energy expenditure and catabolism, leading to weight loss despite adequate caloric intake.
Mutant Huntingtin and Metabolic Dysfunction: The mutant huntingtin (mHtt) protein directly impairs cellular metabolism through multiple mechanisms. mHtt interacts with mitochondria, disrupting dynamics, transport, and function. Additionally, mHtt alters the expression of PGC-1α, a master regulator of mitochondrial biogenesis.
Hypermetabolism and Catabolism: HD patients exhibit resting energy expenditure approximately 20-30% higher than matched controls, despite reduced physical activity. Weight loss, particularly loss of fat-free mass, correlates with faster disease progression and reduced survival.
Advanced Therapeutic Strategies
Targeting metabolic pathways offers disease-modifying potential across neurodegenerative conditions. Several strategies show promise based on underlying mechanisms:
Ketogenic Diet Interventions
- Provides alternative fuel via ketone bodies
- Bypasses impaired glucose metabolism
- Shown benefit in AD, PD, and ALS models
- Human trials ongoing for all three conditions
Mitochondrial Biogenesis Enhancement
- PGC-1α activation through exercise or pharmacologic agents
- TFAM upregulation for mitochondrial DNA replication
- NAD+ precursors to enhance sirtuin activity
Metabolic Flexibility Restoration
- Targeting insulin signaling pathways
- AMPK activators to enhance cellular energy sensing
- mTOR inhibition to promote autophagy
Advanced Clinical Trial Landscape
| Agent | Target | Disease | Phase | Status |
|-------|--------|---------|-------|--------|
| Pioglitazone | PPAR-γ | AD | 3 | Active |
| CoQ10 | Mitochondria | PD | 3 | Completed |
| Creatine | ATP | PD/ALS | 3 | Completed |
| Ketone esters | Metabolism | AD/PD | 2 | Active |
Mermaid diagram (expand to render)
Cross-Links to Related Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Insulin Signaling in AD](/mechanisms/insulin-signaling-ad)
- [Ketogenic Diet in Neurodegeneration](/therapeutics/ketogenic-diet-neurodegeneration)
- [Adult Hippocampal Neurogenesis](/mechanisms/neurogenesis-ad-superagers)
- [Neuroinflammation](/mechanisms/neuroinflammation)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Insulin Signaling in AD](/mechanisms/insulin-signaling-ad)
- [Adult Hippocampal Neurogenesis](/mechanisms/neurogenesis-ad-superagers)
- [Neuroinflammation](/mechanisms/neuroinflammation)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Attwell D, Laughlin SB, An energy budget for signaling in the grey matter of the brain (2001)](https://pubmed.ncbi.nlm.nih.gov/11706622/)
[Cunnane SC, Trushina E, Morland C, et al, Brain glucose metabolism in health, aging, and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32241993/)
[Sweeney MD, Sagare AP, Zlokovic BV, Blood-brain barrier breakdown in Alzheimer's disease and other neurodegenerative disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29198525/)
[Ames A 3rd, CNS energy metabolism as related to function (2000)](https://pubmed.ncbi.nlm.nih.gov/10818012/)
[van de Haar HJ, Jansen JFA, van Osch MJ, et al, Neurovascular unit imaging: a framework for studying physiological adaptations and pathological changes in the cerebral vasculature (2016)](https://pubmed.ncbi.nlm.nih.gov/27297157/)
[Mergenthaler P, Lindauer U, Dienel GA, et al, Sugar for the brain: the role of glucose in physiological and pathological brain function (2013)](https://pubmed.ncbi.nlm.nih.gov/23959284/)
[Nicholls DG, Mitochondrial calcium function and dysfunction in the central nervous system (2009)](https://pubmed.ncbi.nlm.nih.gov/15852472/)
[Shulman RG, Hyder F, Rothman DL, Cerebral metabolism and the emergent function of neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/12006668/)
[Saraste M, Oxidative phosphorylation at the fin de siècle (1999)](https://pubmed.ncbi.nlm.nih.gov/10604464/)
[Kann O, Kuhlkamp T, Engelmann LC, et al, Voltage-gated Ca2+ currents and their mitochondrial contribution in the presynaptic nerve terminal (2006)](https://pubmed.ncbi.nlm.nih.gov/16803845/)
[Pellerin L, Magistretti PJ, Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization (1994)](https://pubmed.ncbi.nlm.nih.gov/7961915/)
[Brown AM, Brain glycogen re-awakened (2004)](https://pubmed.ncbi.nlm.nih.gov/15576002/)
[van den Heuvel MP, Kandel ER, Brain networks, from neurons to societies (2015)](https://pubmed.ncbi.nlm.nih.gov/25937356/)
[Hertz L, The glutamate-GABA-glutamine cycle: an overview, with emphasis on the role of glutamate in GABA synthesis and removal (2009)](https://pubmed.ncbi.nlm.nih.gov/19818465/)
[Mosconi L, Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15602730/)
[Jack CR Jr, Knopman DS, Jagust WJ, et al, Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010)](https://pubmed.ncbi.nlm.nih.gov/20083042/)
[Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al, Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums (2018)](https://pubmed.ncbi.nlm.nih.gov/29566779/)
[de la Monte SM, Wands JR, Alzheimer's disease is type 3 diabetes-evidence reviewed (2008)](https://pubmed.ncbi.nlm.nih.gov/19013169/)
[Swerdlow RH, Kish SJ, Mitochondria in Alzheimer's disease (2002)](https://pubmed.ncbi.nlm.nih.gov/12445501/)
[Manczak M, Anekonda TS, Henson E, et al, Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression (2006)](https://pubmed.ncbi.nlm.nih.gov/16505187/)
[Sheng B, Wang X, Su B, et al, Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22705714/)
[Alano CC, Garnier P, Ying W, et al, NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death (2010)](https://pubmed.ncbi.nlm.nih.gov/20482438/)
[Craft S, Baker LD, Montine TJ, et al, Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial (2012)](https://pubmed.ncbi.nlm.nih.gov/22037104/)
[Eidelberg D, Takikawa S, Moeller JR, et al, The metabolic topography of Parkinsonism (1995)](https://pubmed.ncbi.nlm.nih.gov/7885465/)
[Schapira AH, Mitochondrial dysfunction in Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/16128461/)
[Hu G, Jousilahti P, Bidel S, et al, Type 2 diabetes and the risk of Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17460449/)
[Veech RL, The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism (2004)](https://pubmed.ncbi.nlm.nih.gov/15055346/)
[Pierre K, Pellerin L, Monocarboxylate transporters in the central nervous system: distribution, regulation and function (2005)](https://pubmed.ncbi.nlm.nih.gov/15620683/)
[Broom GM, Shaw IC, Rucklidge JJ, The ketogenic diet as a potential treatment for Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30763158/)
[Krikorian R, Shidler MD, Dangelo K, et al, Dietary ketosis improves memory in mild cognitive impairment (2012)](https://pubmed.ncbi.nlm.nih.gov/22170357/)
[Phillips MCL, Murtagh DKJ, Gilbertson LJ, et al, Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial (2018)](https://pubmed.ncbi.nlm.nih.gov/30149876/)
[Newport MT, VanItallie TB, Kashiwaya Y, et al, A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25499957/)
[Chang TY, Yamauchi Y, Hasan MT, et al, Cellular cholesterol homeostasis and Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28456780/)
[Cutler RG, Kelly J, Storie K, et al, Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease (2004)](https://pubmed.ncbi.nlm.nih.gov/14749433/)
[Huang Y, Mucke L, Alzheimer mechanisms and therapeutic strategies (2012)](https://pubmed.ncbi.nlm.nih.gov/22940876/)
[Schousboe A, Waagepetersen HS, Role of astrocytes in glutamate homeostasis: implications for excitotoxicity (2005)](https://pubmed.ncbi.nlm.nih.gov/15935491/)
[Choi DW, Excitotoxicity (2003)](https://pubmed.ncbi.nlm.nih.gov/14578017/)
[Schwarcz R, Bruno JP, Muchowski PJ, et al, Kynurenines in the mammalian brain: when physiology meets pathology (2012)](https://pubmed.ncbi.nlm.nih.gov/22727062/)
[Cotman CW, Berchtold NC, Christie LA, Exercise builds brain health: key roles of growth factor cascades and inflammation (2007)](https://pubmed.ncbi.nlm.nih.gov/17884808/)
[Mattson MP, Energy intake, meal frequency, and health: a neurobiological perspective (2005)](https://pubmed.ncbi.nlm.nih.gov/15860453/)